Nature Biotechnology· M. Frank Erasmus, Daniel Bedinger, Elizabeth Hopkins, Ginger Ferguson, Justine Strickler, Christilyn P. Graff, Samantha R. Summers, Stacy L. Capehart, Joshua D. Slocum, Crystal Richardson, Sumit Kumar, Zhifei Sun, Yujie Shang, Jixian Zhang, Ming Gu, Lixia Yi, Alon Wellner, Shuangjia Zheng, Wei Lu, Pietro Sormanni, Matthew Greenig, Haiping Zhang, Brendan T. Mann, Mahdi Baghbanzadeh, Ali Rahnavard, Gregory L. Moore, Huaiyu Sun, Ying Ding, Alex Nisthal, Jitendra Kanodia, Matthew J. Bernett, Aurélien Pélissier, Yanjun Shao, Maria Rodriguez Martinez, Karthik Ramesh, Horacio Nastri, Andreas Evers, Anhar Abdelatif, Andrew J. Bordner, Mykola Bordyuh, Lim Heo, Brian A. Kidd, H. Serhat Tetikol, Shuai Wei, Jung-Eun Shin, Ryan Peckner, Leigh Manley, Ajitesh Lunge, Yashas Devasurmutt, Bora Guloglu, Liviu Copoiu, Miles McGibbon, Monica L. Fernandez-Quintero, Nitesh Mishra, Sean M. Callaghan, Olivia M. Swanson, Daniel L. V. Bader, James A. Ferguson, Sai S. R. Raghavan, Benjamin Nemoz, Colleen A. Maillie, Charles Bowman, Bryan Briney, Andrew B. Ward, Paolo Marcatili, Rahmad Akbar, Bing He, Fandi Wu, Jianhua Yao, Bin Hu, Michal Kucer, Kaetlyn Rose Gibson, Rahul Somasundaram, Li-Wei Hung, Tomasz Kaszuba, Daved H. Fremont, Hyeongsun Jeong, Vinodh Babu Kurella, Shipra Malhotra, Satyendra Kumar, Yanyun Liu, Lingling Xu, Joshua Misa, Alexander Nicholas St. John, Jeff Vogt, Fátima A. Dávila-Hernández, Da Xu, Michael Chungyoun, Zyaja D. Huggan, Jeffrey J. Gray, Jonathan Parkinson, Young Su Ko, Wei Wang, Franziska Geiger, Jonathon D. Ziegler, Nikhil Haas, Chance Challacombe, Ahmad Qamar, Akshita Singh, Yi-Ching Tang, Zhiqiang An, Xiaoqian Jiang, Yejin Kim, Xinyan Zhao, Erik Swanson, Jürgen Klattig, Karsten Winkler, Tschimegma Bataa, Volker Sandig, Lilian Denzler, Chunan Liu, Randall J. Brezski, Laura Spector, Katheryn Perea-Schmittle, Sara D’Angelo, Fortunato Ferrara, Andrew R. M. Bradbury·· 2026-08-19精选AI 评分88
AIntibody前瞻性盲测：以实验亲和力与可开发性为锚评测计算抗体发现
A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability
AI 导读
【全文节选总结】AIntibody挑战以SARS-CoV-2 RBD为靶点，对25家以上机构提交的511条抗体序列统一表达为全长IgG，用高通量SPR、KinExA和五项可开发性检测做前瞻性盲测。
推荐理由
前瞻性盲测把AI设计的抗体统一表达为IgG并做SPR、KinExA与可开发性检测，给出算法与实验方法在同一条件下的对照。
来源：Nature Biotechnology · doi.org